Why the study?
Does the mechanism of platelet P2Y12 receptor inhibition (reversible vs irreversible) determine the attributable safety profile and bleeding risk in patients with ACS or undergoing PCI?
Does the mechanism of platelet P2Y12 receptor inhibition (reversible vs irreversible) determine the attributable safety profile and bleeding risk in patients with ACS or undergoing PCI?
This review highlights the importance of understanding how reversible versus irreversible mechanisms of P2Y12 receptor inhibition impact bleeding risk and safety profiles.
Answers are grounded in this paper and cite their sources.
May inform bleeding risk assessment with P2Y12 inhibitors; leaves open whether mechanism-specific choices improve outcomes in ACS/PCI.
The platelet P2Y12 receptor is involved in all aspects of arterial thrombosis, including adhesion, activation, aggregation, secretion and development of a stable aggregate on which coagulation proteins can assemble and fibrin strands can mesh. Inhibition of the P2Y12 receptor has been shown convincingly to reduce cardiovascular events among patients with acute coronary syndromes (ACS) and in patients undergoing percutaneous intervention (PCI). Current studies are exploring whether there is a threshold of platelet aggregation below which only more bleeding occurs, without a concomitant reduction in clinical events. The following review considers the potential relevance of reversible and irreversible mechanisms of P2Y12 inhibition to bleeding risk, posing the question, "Is it not only how much but how a platelet P2Y12 receptor is inhibited that determines the attributable safety profile?"
No takes yet. Share an insight, caveat, or question.
Becker et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: